
Celldex Therapeutics (CLDX) Stock Forecast & Price Target
Celldex Therapeutics (CLDX) Analyst Ratings
Bulls say
Celldex Therapeutics Inc. demonstrates a robust financial position, ending the year with $725.3 million in cash, which is projected to support operations through 2027. The significant clinical advancements of barzolvolimab have resulted in up to 82% of patients with chronic spontaneous urticaria experiencing well-controlled conditions, alongside enhanced quality of life metrics. Additionally, the potential for barzolvolimab to achieve meaningful improvements in dysphagia could position it strongly against competitors, underscoring the company's innovative edge in the immunotherapy landscape.
Bears say
Celldex Therapeutics faces substantial risks related to the execution of its drug development and commercialization strategy, as failure in clinical trials could result in the rejection of regulatory approvals and diminish market potential. The company's reliance on securing adequate funding to advance its therapeutics through development is also a pressing concern, with the possibility of unsuccessful trials significantly impeding financial stability. Furthermore, although Celldex possesses a differentiated platform, competitive pressures may limit the adoption of its products, adding to the uncertainty surrounding the company's future prospects.
This aggregate rating is based on analysts' research of Celldex Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Celldex Therapeutics (CLDX) Analyst Forecast & Price Prediction
Start investing in Celldex Therapeutics (CLDX)
Order type
Buy in
Order amount
Est. shares
0 shares